An Extension and Crossover Vaccination Study on the Immune Response and Safety of a Vaccine Against Respiratory Syncytial Virus Given to Adults 60 Years of Age and Above Who Participated in RSV OA=ADJ-006 Study

This study is specifically for people who have already taken part in an earlier RSV vaccine study called RSV OA=ADJ-006. You must be aged 60 or older. You could have either received the actual RSVPreF3 OA vaccine or a dummy treatment (placebo) in that previous study.

It's important that you are generally healthy enough to take part and can follow the study's instructions. This includes being able to attend appointments, use a phone or other communication, and keep track of things in a diary if needed. You also need to be able to understand and agree to what the study involves.

However, there are some reasons why you wouldn't be able to join. If you have an illness that affects your immune system, or if you've had a bad reaction to vaccines before, you wouldn't be suitable. Also, if you have a serious or unstable long-term illness, certain neurological problems, or any condition that a doctor thinks would make taking part unsafe or difficult, you wouldn't be able to join.

If you join this study, it builds on your previous participation in the RSV OA=ADJ-006 study. You will likely continue to have contact with the study team, which could involve phone calls or visits to the study clinic. These visits are important for the team to check your health, see how you're feeling, and potentially give you a vaccine dose if you previously received the placebo. They will also collect information about your general health and any potential side effects. You might be asked to keep a diary of how you feel. The study aims to follow participants for up to five years (about 60 months) to understand the vaccine's long-term effects and safety.